Driehaus Capital Management’s AnaptysBio ANAB Stock Holding History

Driehaus Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-120,000	Closed	-$2.59M	–	429
2021 Q1	$2.59M	Buy	120,000 +80,000	+200%	+$2.02M	0.04%	313
2020 Q4	$860K	Buy	+40,000	New	+$971K	0.01%	332
2018 Q2	–	Sell	-46,914	Closed	-$4.88M	–	465
2018 Q1	$4.88M	Buy	+46,914	New	+$5.29M	0.17%	154

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Driehaus Capital Management's ANAB Position: Q2 2021 in Review

Driehaus Capital Management sold out of AnaptysBio (ANAB) in Q2 2021, closing a stake of 120,000 shares — an estimated $2.59M sold.

Driehaus Capital Management first reported a position in ANAB in Q1 2018 and held it in 3 quarters. The position peaked at $4.88M in Q1 2018. 122 funds tracked by Wall St. Rank hold ANAB as of Q2 2021.

Driehaus Capital Management reported no remaining AnaptysBio position as of Q2 2021 after selling out during the quarter.
Driehaus Capital Management sold 120,000 AnaptysBio shares in Q2 2021, an estimated $2.59M.
Driehaus Capital Management first reported a position in AnaptysBio in Q1 2018 and held it in 3 quarters.
Driehaus Capital Management's AnaptysBio position peaked at $4.88M in Q1 2018.
122 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2021.

Based on Driehaus Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.